Targeted drugs for the treatment of melanoma dabrafenib $11,085.6/box (75mg*120 capsules), trametinib $11,085/box (2mg*30 capsules). Melanoma is a malignant tumor originating from the skin, with a high degree of malignancy, and is prone to metastasis and proliferation, but there are targeted targeted drugs, commonly used in the clinic, including Darafenib and Trametinib, which have been included in the scope of the medical insurance, with the price of $11,085.6/box (75mg*120 capsules) and $11,085/box (2mg*30 capsules), which should be combined with the local medical insurance policy to determine. Melanoma targeted drugs can be a single drug treatment, can also be combined with drugs, specific need to combine with the patient’s condition to determine, during the treatment period may appear bleeding, venous thrombosis, alopecia, pawpaw syndrome and other adverse reactions, need to be timely and symptomatic treatment.